The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hi Rhodi, please give me details of your charity raise. Do you have a just giving link?
As you say Rhodi, it’s a shame; this board was very useful for years, with a good mix of contributors. I am always interested in mixed views, but NOT stupid random comments which only deters sensible contribution. This could go a number of ways, do it will be interesting to see if there is now going to be a change in strategy. Lots of options but hopefully not selling out any of them on the cheap.
Why has it taken 2 years to get this published in this reputable journal? New bosses and new PR impetus? The trials referred to in the article were completed 2 years ago, with no reference to the recent Nebulised trial or DDP trials.
Am I missing something?
I can’t work out if this is good or bad, but I agree the the sentiments of Chester.
Thank you Rhodi for your extensive comments which are always appreciated.
This price action is indeed crazy bearing in mind that we hit £2 two years ago based on previous P2 trials.
As of 30sep we had £40m in cash, full stated intention to partner DPI/MDI and I would suggest go alone with lucrative Nebulised version.
DPI trials equal success to latest trial and full expectation for MDI to report first part Q1.
I would expect partnering of DPI/MDI with staged payments and royalties linked to milestones. “hopefully” a good up front payment to add to existing cash to support P3 for Nebulised version. However I would value factual opinions as to the likely cost of the said P3.
However, based on where we are with the results and the pipeline, this SP is crazy.
Big relief and very happy for all LTH’s and fellow investors. MDI results next, of which I am also confident of success, based on DPI and now Nebulised compounds. I am hoping for out licensing agreements for DPI/MDI as always stated, and a good upfront payment would probably fund P3 for Nebulized version. We also still have cash in the bank. Hold on tight guys.
I must say that I don’t get why they would issue an RNS stating that they were going to release an RNS?
Why a CC on the same day? My confidence level would have been higher if they said nothing.
GL all.
Thank you Buddy for the good wishes and good luck to all in 2020. HNY
My mistake, it should have read 8 uk shares to 1 ADS. Maths already well explained. Original RNS was 27/04/2017.
Thanks for link Oilspec and I would be delighted if we get to that level. However, there are eight ADS shares to our uk one and then you gave the exchange rate. However, things are hotting up. GLA and especially LTH’s. Happy new year.
Isthisawinner, i take it back regarding MDI data where part 1 is NOW due QI according to RNS of 05/11. So it has slipped from the original target of H2-19 from the initiation of trial RNS 04/06/19 with no explanation why!
"The Phase 2 trial using the MDI formulation has a randomized, double-blind, placebo-controlled, two-part design. The Company anticipates reporting data from the first part of the trial in the second half of 2019, with final data expected in the first quarter of 2020"
However the larger Nebulized trial data is due, as you say, "around year end", so hopefully they can stick to that one.
we need the luck with these guys!
Its not just MDI news due, but also the Nebulised (400 patient) trial. Its also about the company retailing credibility with their statements and promises.
Rhodi, you are right about the details on LSE, but you can see the history ok on ADVFN
Rhodi, I agree that the statement is nothing new, however, we now have the benefit of a formula/ delivery system and successful trials of DPI. The statement was contained in the RNS initiating the DPI trials in June. So I guess we can assume similar results to that of DPI. I would imagine that the DPI/MDI trials and partnering strategy for these product lines were part of the massive II investment a couple of years back. I also note that the target end points of these trials and indeed the latest nebuliser trial, seems to now focus on what we know works, namely improved FEV. I believe that the latest trials are really focusing on the what works rather than speculation. IF this proves to be true by getting positive trial results imminently, HOPEFULLY we may get somewhere. Good luck to you all LTH’s and I hope we all have a good 2020.
From initiation of trial RNS:
“We plan to seek a strategic partner to develop and commercialize inhalers of ensifentrine to maximize the significant potential value from this opportunity.”
I don’t follow the shorts Rhodi, which is interesting, however, I did post this inNovember, which I believe still stands! IE no news released to say NOT.
Positives19 Nov '19
Hang in there guys !
1. MDI part one data imminent
2. Nebuliser trial data year end.
3. DPI/MDI has always been declared as an out license opportunity, and DPI trial met all end points, so a deal “could be struck” at any time.( Hopefully before pigs fly)
4. Nebuliser version, they will likely sell direct.
Interesting year end I would say.
Good luck to us all LTH.
As far as I can see, only circa 20% of shares outside of declared II’s and directors, so Ifffff this ever starts to move on good news, it should fly. However, too many false dawns and I agree with Rhodi: If we get to £2, then greater things will follow. Not sure why we haven’t heard about results of part 1 of the MDI trial yet? As the similar DPI part one was reported well inside the current timeline. Also strange that it wasn’t mentioned in the last update.
Black Friday came today for JAK, great reward for terrible SP performance. It’s about time that these options were issued at an exercise price way above where we are now, designed to incentivise and not a reward for poor performance.
Hang in there guys !
1. MDI part one data imminent
2. Nebuliser trial data year end.
3. DPI/MDI has always been declared as an out license opportunity, and DPI trial met all end points, so a deal “could be struck” at any time.( Hopefully before pigs fly)
4. Nebuliser version, they will likely sell direct.
Interesting year end I would say.
Good luck to us all LTH.
We should receive the first part of the trail data imminently.
In theory if should be very similar to the DPI. Second half due in Q1 next year.
It’s always been their plan to out license DPI/MDI, so hopefully that won’t be too far away next year if Mdi trials are as successful as the Dpi.
The Nebulused version they will take into Ph3 next year. I also note that only circa 20% of shares are in free float, so IiiiiiiiiF this ever takes off, it will hopefully move quickly. Good luck LTH’s, you know who you are. Over 20% of adult life spent waiting for “significant “ shareholder value.!!!!